Inari Medical, Inc. (NARI)周六晚间股价大涨12.03%,引发了市场广泛关注。主导这一涨势的主因来自于公司2024年第三季度业绩数据超出预期。
该公司Q3财报显示,调整后每股亏损为9美分,优于华尔街分析师预期的11美分亏损。营收方面,公司本季度实现营收1.5339亿美元,同比增长21.4%,也高于市场预期水平。
作为一家新兴的医疗器械公司,Inari Medical过去几个季度持续保持高速增长,受到分析师普遍看好。即便本季度仍处于亏损状态,但良好的业绩预期和未来发展潜力使其股价获得提振。目前,分析师给予Inari Medical一致的"买入"评级,认为公司长期成长空间广阔。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.